| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myelodysplastic Syndromes | 12 | 2025 | 87 | 1.370 |
Why?
|
| Biomarkers, Tumor | 34 | 2025 | 504 | 1.360 |
Why?
|
| Racemases and Epimerases | 15 | 2006 | 24 | 1.160 |
Why?
|
| Adenocarcinoma | 20 | 2014 | 338 | 1.060 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 3 | 2022 | 46 | 0.880 |
Why?
|
| Prostatic Neoplasms | 15 | 2006 | 403 | 0.860 |
Why?
|
| Immunohistochemistry | 29 | 2025 | 892 | 0.850 |
Why?
|
| RNA-Binding Proteins | 13 | 2014 | 433 | 0.800 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 9 | 2016 | 68 | 0.710 |
Why?
|
| Herpesvirus 4, Human | 11 | 2016 | 196 | 0.670 |
Why?
|
| Multiple Myeloma | 2 | 2022 | 349 | 0.620 |
Why?
|
| Mutation | 14 | 2025 | 2604 | 0.570 |
Why?
|
| Bone Marrow | 15 | 2014 | 181 | 0.550 |
Why?
|
| Neoplasm Proteins | 9 | 2012 | 280 | 0.530 |
Why?
|
| Biopsy, Needle | 8 | 2006 | 137 | 0.530 |
Why?
|
| Leukemia, Myeloid, Acute | 5 | 2025 | 192 | 0.530 |
Why?
|
| In Situ Hybridization, Fluorescence | 7 | 2016 | 168 | 0.490 |
Why?
|
| Hodgkin Disease | 3 | 2013 | 55 | 0.460 |
Why?
|
| Humans | 144 | 2025 | 63149 | 0.460 |
Why?
|
| Tumor Suppressor Protein p53 | 7 | 2025 | 304 | 0.420 |
Why?
|
| Graft vs Host Disease | 3 | 2013 | 111 | 0.420 |
Why?
|
| Aged, 80 and over | 30 | 2025 | 5429 | 0.420 |
Why?
|
| Lymphoma, Follicular | 2 | 2013 | 16 | 0.420 |
Why?
|
| Male | 95 | 2025 | 29717 | 0.410 |
Why?
|
| Clonal Evolution | 1 | 2013 | 6 | 0.410 |
Why?
|
| Diabetes Mellitus, Experimental | 8 | 2000 | 199 | 0.400 |
Why?
|
| Bone Marrow Transplantation | 2 | 2013 | 139 | 0.400 |
Why?
|
| Killer Cells, Natural | 12 | 2010 | 217 | 0.380 |
Why?
|
| Middle Aged | 51 | 2025 | 17480 | 0.380 |
Why?
|
| Female | 83 | 2025 | 32709 | 0.380 |
Why?
|
| Bone Marrow Diseases | 2 | 2008 | 14 | 0.370 |
Why?
|
| Lymphoproliferative Disorders | 6 | 2012 | 39 | 0.370 |
Why?
|
| Lymphoma, B-Cell | 5 | 2016 | 61 | 0.370 |
Why?
|
| Antibodies, Monoclonal | 21 | 2006 | 862 | 0.360 |
Why?
|
| Carcinoma | 5 | 2006 | 122 | 0.360 |
Why?
|
| T-Lymphocytes | 17 | 2012 | 1007 | 0.350 |
Why?
|
| Aged | 46 | 2025 | 14333 | 0.350 |
Why?
|
| Lymphoma, Non-Hodgkin | 4 | 1999 | 54 | 0.340 |
Why?
|
| Islets of Langerhans | 7 | 2007 | 279 | 0.340 |
Why?
|
| Prognosis | 16 | 2025 | 1741 | 0.340 |
Why?
|
| Precancerous Conditions | 4 | 2014 | 70 | 0.330 |
Why?
|
| Carcinoma, Renal Cell | 4 | 2018 | 93 | 0.330 |
Why?
|
| Kidney Neoplasms | 4 | 2018 | 146 | 0.310 |
Why?
|
| High-Throughput Nucleotide Sequencing | 4 | 2025 | 312 | 0.310 |
Why?
|
| Colonic Neoplasms | 6 | 2003 | 221 | 0.310 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 6 | 2010 | 49 | 0.310 |
Why?
|
| Hemoglobinuria, Paroxysmal | 1 | 2008 | 5 | 0.300 |
Why?
|
| Lymphocytes | 11 | 2008 | 201 | 0.300 |
Why?
|
| Eukaryotic Initiation Factor-2 | 4 | 2008 | 15 | 0.290 |
Why?
|
| Adult | 41 | 2025 | 16736 | 0.290 |
Why?
|
| Rats | 31 | 2009 | 1977 | 0.290 |
Why?
|
| Alveolitis, Extrinsic Allergic | 1 | 2008 | 15 | 0.290 |
Why?
|
| Histocompatibility Antigens | 10 | 1994 | 106 | 0.280 |
Why?
|
| Rats, Inbred Strains | 9 | 2009 | 149 | 0.280 |
Why?
|
| B-Lymphocytes | 7 | 2016 | 574 | 0.280 |
Why?
|
| Red-Cell Aplasia, Pure | 1 | 2007 | 2 | 0.280 |
Why?
|
| Uterine Cervical Neoplasms | 4 | 2011 | 140 | 0.270 |
Why?
|
| Myeloproliferative Disorders | 4 | 2014 | 16 | 0.270 |
Why?
|
| Diabetes Mellitus, Type 1 | 9 | 2009 | 621 | 0.260 |
Why?
|
| DNA-Binding Proteins | 4 | 2024 | 1183 | 0.260 |
Why?
|
| Prostate | 6 | 2006 | 85 | 0.250 |
Why?
|
| Neoplasm Staging | 9 | 2016 | 490 | 0.250 |
Why?
|
| Lymphoma | 7 | 2012 | 102 | 0.250 |
Why?
|
| Melanoma | 4 | 2014 | 331 | 0.240 |
Why?
|
| Immunoenzyme Techniques | 16 | 2011 | 107 | 0.240 |
Why?
|
| Dioxygenases | 2 | 2024 | 25 | 0.240 |
Why?
|
| Receptors, Antigen, B-Cell | 7 | 1988 | 60 | 0.240 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2016 | 520 | 0.230 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 2 | 2016 | 30 | 0.230 |
Why?
|
| Urinary Bladder Neoplasms | 3 | 2016 | 98 | 0.220 |
Why?
|
| Membrane Proteins | 7 | 2010 | 894 | 0.220 |
Why?
|
| Cytoskeletal Proteins | 3 | 2010 | 200 | 0.220 |
Why?
|
| Immunoglobulin lambda-Chains | 3 | 2022 | 10 | 0.220 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2016 | 108 | 0.220 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 3 | 2014 | 51 | 0.210 |
Why?
|
| Sensitivity and Specificity | 12 | 2016 | 1143 | 0.210 |
Why?
|
| Immunoglobulin kappa-Chains | 2 | 2022 | 9 | 0.210 |
Why?
|
| Macrophages | 6 | 2011 | 1038 | 0.210 |
Why?
|
| Phenotype | 13 | 2016 | 1199 | 0.210 |
Why?
|
| Epstein-Barr Virus Infections | 4 | 2013 | 103 | 0.210 |
Why?
|
| Cytoskeleton | 6 | 1988 | 138 | 0.210 |
Why?
|
| Membrane Glycoproteins | 6 | 2011 | 668 | 0.210 |
Why?
|
| Cytosine | 2 | 2014 | 31 | 0.200 |
Why?
|
| Nevus | 2 | 2014 | 22 | 0.200 |
Why?
|
| Bone Marrow Cells | 8 | 2009 | 238 | 0.200 |
Why?
|
| Peptide Initiation Factors | 2 | 2001 | 33 | 0.200 |
Why?
|
| Rats, Inbred BB | 5 | 1994 | 134 | 0.200 |
Why?
|
| Radiation Tolerance | 4 | 2016 | 52 | 0.190 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 2 | 2013 | 10 | 0.190 |
Why?
|
| Immunologic Capping | 7 | 1983 | 10 | 0.190 |
Why?
|
| Animals | 54 | 2016 | 20613 | 0.190 |
Why?
|
| Flow Cytometry | 7 | 2009 | 660 | 0.190 |
Why?
|
| Epigenesis, Genetic | 3 | 2016 | 387 | 0.190 |
Why?
|
| Intestinal Mucosa | 5 | 2010 | 245 | 0.180 |
Why?
|
| 5-Methylcytosine | 3 | 2016 | 21 | 0.180 |
Why?
|
| Lung Neoplasms | 5 | 2014 | 663 | 0.180 |
Why?
|
| Uterine Cervical Dysplasia | 2 | 2011 | 29 | 0.180 |
Why?
|
| Proto-Oncogene Proteins | 5 | 2024 | 324 | 0.180 |
Why?
|
| Neoplasms | 7 | 2016 | 1358 | 0.180 |
Why?
|
| Survival Analysis | 9 | 2018 | 579 | 0.180 |
Why?
|
| Spleen | 16 | 2012 | 483 | 0.180 |
Why?
|
| T-Lymphocyte Subsets | 4 | 2008 | 248 | 0.170 |
Why?
|
| Leukemia, Neutrophilic, Chronic | 1 | 2020 | 4 | 0.170 |
Why?
|
| Pancreatic Neoplasms | 3 | 2010 | 341 | 0.170 |
Why?
|
| Leukocytosis | 1 | 2020 | 13 | 0.170 |
Why?
|
| Chromosome Aberrations | 4 | 2008 | 67 | 0.170 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2014 | 447 | 0.160 |
Why?
|
| Diagnosis, Differential | 9 | 2018 | 969 | 0.160 |
Why?
|
| Colon | 3 | 2003 | 146 | 0.160 |
Why?
|
| Polymerase Chain Reaction | 6 | 2016 | 517 | 0.160 |
Why?
|
| Cystadenocarcinoma, Serous | 2 | 2011 | 13 | 0.160 |
Why?
|
| Carcinoma, Endometrioid | 2 | 2011 | 19 | 0.160 |
Why?
|
| Oncogenes | 2 | 2018 | 68 | 0.160 |
Why?
|
| T-Lymphocytes, Cytotoxic | 4 | 2000 | 181 | 0.160 |
Why?
|
| Adenoma | 5 | 2009 | 68 | 0.160 |
Why?
|
| Eosinophilia | 3 | 2008 | 32 | 0.160 |
Why?
|
| Endometrial Neoplasms | 2 | 2011 | 55 | 0.150 |
Why?
|
| Islets of Langerhans Transplantation | 4 | 2007 | 176 | 0.150 |
Why?
|
| Mitoxantrone | 1 | 2018 | 16 | 0.150 |
Why?
|
| Induction Chemotherapy | 1 | 2018 | 41 | 0.150 |
Why?
|
| Carcinoma in Situ | 2 | 2010 | 35 | 0.150 |
Why?
|
| Rats, Inbred Lew | 10 | 2009 | 106 | 0.150 |
Why?
|
| Carcinoma, Papillary | 2 | 2008 | 35 | 0.140 |
Why?
|
| Urothelium | 2 | 2016 | 22 | 0.140 |
Why?
|
| Retinoblastoma Binding Proteins | 1 | 2018 | 6 | 0.140 |
Why?
|
| Receptor, ErbB-4 | 1 | 2018 | 10 | 0.140 |
Why?
|
| Adenoma, Oxyphilic | 1 | 2018 | 11 | 0.140 |
Why?
|
| Heterozygote | 2 | 2016 | 169 | 0.140 |
Why?
|
| Carcinoma, Pancreatic Ductal | 2 | 2010 | 111 | 0.140 |
Why?
|
| Leukemia | 4 | 2013 | 62 | 0.140 |
Why?
|
| Interleukin Receptor Common gamma Subunit | 2 | 2008 | 78 | 0.140 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2013 | 718 | 0.140 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 2 | 2008 | 7 | 0.140 |
Why?
|
| Intestinal Neoplasms | 1 | 1997 | 14 | 0.140 |
Why?
|
| Skin Neoplasms | 3 | 2014 | 412 | 0.140 |
Why?
|
| Predictive Value of Tests | 7 | 2016 | 1082 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-abl | 1 | 2016 | 6 | 0.130 |
Why?
|
| Papillomavirus Infections | 2 | 2011 | 129 | 0.130 |
Why?
|
| Herpesviridae Infections | 3 | 1996 | 27 | 0.130 |
Why?
|
| Rats, Mutant Strains | 4 | 1991 | 10 | 0.130 |
Why?
|
| Gene Deletion | 1 | 2018 | 307 | 0.130 |
Why?
|
| Histiocytic Sarcoma | 1 | 2016 | 4 | 0.130 |
Why?
|
| Hemoglobin C | 1 | 2016 | 2 | 0.130 |
Why?
|
| Anemia, Hypochromic | 1 | 2016 | 5 | 0.130 |
Why?
|
| Hemoglobins, Abnormal | 1 | 2016 | 6 | 0.130 |
Why?
|
| B7-H1 Antigen | 1 | 2016 | 57 | 0.130 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2007 | 125 | 0.130 |
Why?
|
| Sarcoma | 1 | 2016 | 36 | 0.120 |
Why?
|
| Histiocytosis, Non-Langerhans-Cell | 2 | 1993 | 3 | 0.120 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2018 | 220 | 0.120 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2016 | 40 | 0.120 |
Why?
|
| Eukaryotic Initiation Factor-4E | 3 | 2008 | 16 | 0.120 |
Why?
|
| Cell Polarity | 3 | 2010 | 109 | 0.120 |
Why?
|
| Burkitt Lymphoma | 2 | 2016 | 73 | 0.120 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 2 | 2006 | 4 | 0.120 |
Why?
|
| Treatment Failure | 2 | 2013 | 199 | 0.120 |
Why?
|
| Adenoma, Villous | 1 | 1995 | 1 | 0.120 |
Why?
|
| Lymphocyte Function-Associated Antigen-1 | 3 | 2003 | 14 | 0.120 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 3 | 2003 | 15 | 0.120 |
Why?
|
| Intercellular Adhesion Molecule-1 | 3 | 2003 | 54 | 0.120 |
Why?
|
| Immunophenotyping | 6 | 2016 | 195 | 0.120 |
Why?
|
| DNA Damage | 3 | 2016 | 280 | 0.120 |
Why?
|
| Cell Transformation, Neoplastic | 5 | 2009 | 206 | 0.110 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 1 | 2014 | 4 | 0.110 |
Why?
|
| Pneumonia | 2 | 2013 | 289 | 0.110 |
Why?
|
| Fixatives | 1 | 2014 | 16 | 0.110 |
Why?
|
| Neoplastic Stem Cells | 3 | 2012 | 205 | 0.110 |
Why?
|
| Cell Adhesion Molecules | 1 | 1995 | 90 | 0.110 |
Why?
|
| Salvage Therapy | 2 | 2013 | 75 | 0.110 |
Why?
|
| ADP Ribose Transferases | 2 | 1991 | 62 | 0.110 |
Why?
|
| Disease Progression | 6 | 2024 | 1166 | 0.110 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 2 | 2012 | 57 | 0.110 |
Why?
|
| Cytotoxins | 1 | 1994 | 12 | 0.110 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2014 | 26 | 0.110 |
Why?
|
| Dendritic Cells | 2 | 2013 | 524 | 0.110 |
Why?
|
| Pathology, Clinical | 1 | 2014 | 21 | 0.110 |
Why?
|
| Cholangiocarcinoma | 1 | 2014 | 30 | 0.110 |
Why?
|
| Antigens, Surface | 7 | 2002 | 196 | 0.110 |
Why?
|
| Antigens, CD34 | 2 | 2011 | 56 | 0.110 |
Why?
|
| Monoclonal Gammopathy of Undetermined Significance | 1 | 2014 | 33 | 0.110 |
Why?
|
| Lung | 3 | 2008 | 952 | 0.100 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2007 | 242 | 0.100 |
Why?
|
| Graft Rejection | 4 | 2007 | 293 | 0.100 |
Why?
|
| Histiocytosis, Sinus | 1 | 1993 | 2 | 0.100 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2014 | 419 | 0.100 |
Why?
|
| Anemia, Hemolytic | 1 | 2013 | 12 | 0.100 |
Why?
|
| Mice | 21 | 2016 | 10816 | 0.100 |
Why?
|
| Neoplasm Grading | 1 | 2013 | 87 | 0.100 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2012 | 25 | 0.100 |
Why?
|
| Biopsy | 5 | 2016 | 433 | 0.100 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2012 | 51 | 0.100 |
Why?
|
| Fatal Outcome | 1 | 2013 | 124 | 0.100 |
Why?
|
| Skin Transplantation | 4 | 2002 | 156 | 0.100 |
Why?
|
| Lymphocytic Choriomeningitis | 4 | 2002 | 53 | 0.100 |
Why?
|
| Gastric Mucosa | 2 | 2010 | 53 | 0.100 |
Why?
|
| Erythrocytes | 2 | 1987 | 149 | 0.100 |
Why?
|
| Young Adult | 7 | 2018 | 4673 | 0.100 |
Why?
|
| CD40 Ligand | 6 | 2002 | 158 | 0.100 |
Why?
|
| Stomach Neoplasms | 2 | 2010 | 78 | 0.090 |
Why?
|
| Human papillomavirus 18 | 1 | 2011 | 4 | 0.090 |
Why?
|
| Adrenal Glands | 1 | 2012 | 33 | 0.090 |
Why?
|
| Human papillomavirus 16 | 1 | 2011 | 17 | 0.090 |
Why?
|
| Immunologic Deficiency Syndromes | 2 | 2013 | 72 | 0.090 |
Why?
|
| Autoimmunity | 2 | 2006 | 238 | 0.090 |
Why?
|
| Tumor Virus Infections | 3 | 1997 | 36 | 0.090 |
Why?
|
| Mice, Inbred C57BL | 12 | 2016 | 3387 | 0.090 |
Why?
|
| Disease-Free Survival | 4 | 2014 | 242 | 0.090 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2012 | 144 | 0.090 |
Why?
|
| Organ Transplantation | 1 | 2012 | 54 | 0.090 |
Why?
|
| Pleural Neoplasms | 1 | 2011 | 18 | 0.090 |
Why?
|
| RNA, Viral | 1 | 2013 | 276 | 0.090 |
Why?
|
| Graft Survival | 3 | 2002 | 290 | 0.090 |
Why?
|
| Mesothelioma | 1 | 2011 | 28 | 0.090 |
Why?
|
| Antigens, Neoplasm | 3 | 2008 | 136 | 0.090 |
Why?
|
| Megakaryocytes | 1 | 2011 | 18 | 0.090 |
Why?
|
| Peritoneal Neoplasms | 1 | 2011 | 28 | 0.090 |
Why?
|
| Epithelium | 1 | 2011 | 96 | 0.090 |
Why?
|
| Leukemia, Monocytic, Acute | 1 | 2010 | 4 | 0.090 |
Why?
|
| Genes, X-Linked | 1 | 2011 | 19 | 0.090 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2012 | 96 | 0.090 |
Why?
|
| Endopeptidases | 1 | 2011 | 67 | 0.090 |
Why?
|
| Lymphocyte Depletion | 7 | 2002 | 99 | 0.090 |
Why?
|
| Meningeal Neoplasms | 1 | 2011 | 59 | 0.090 |
Why?
|
| Meningioma | 1 | 2011 | 60 | 0.090 |
Why?
|
| Liver Neoplasms | 1 | 2014 | 297 | 0.090 |
Why?
|
| Neoplasm Metastasis | 2 | 2008 | 201 | 0.090 |
Why?
|
| Immunization | 2 | 2009 | 131 | 0.090 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2012 | 199 | 0.090 |
Why?
|
| NADPH Oxidases | 1 | 2011 | 69 | 0.090 |
Why?
|
| Blotting, Western | 4 | 2014 | 607 | 0.090 |
Why?
|
| Stomach Diseases | 1 | 2010 | 10 | 0.090 |
Why?
|
| Hematopoiesis | 3 | 2008 | 124 | 0.090 |
Why?
|
| Immune Tolerance | 3 | 2000 | 176 | 0.080 |
Why?
|
| Palliative Care | 1 | 2013 | 227 | 0.080 |
Why?
|
| Time Factors | 9 | 2014 | 3754 | 0.080 |
Why?
|
| Karyotyping | 6 | 2011 | 48 | 0.080 |
Why?
|
| Protein Kinase C | 1 | 2010 | 102 | 0.080 |
Why?
|
| Alleles | 2 | 2025 | 447 | 0.080 |
Why?
|
| Autoimmune Diseases | 3 | 1991 | 230 | 0.080 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2011 | 255 | 0.080 |
Why?
|
| Cell Cycle Proteins | 1 | 2012 | 394 | 0.080 |
Why?
|
| Lymphopenia | 2 | 1987 | 34 | 0.080 |
Why?
|
| Leukemia, Myeloid, Chronic-Phase | 1 | 2009 | 6 | 0.080 |
Why?
|
| Basophils | 1 | 2009 | 14 | 0.080 |
Why?
|
| Survival Rate | 5 | 2011 | 846 | 0.080 |
Why?
|
| DNA Mutational Analysis | 3 | 2016 | 195 | 0.080 |
Why?
|
| Homeostasis | 1 | 2012 | 370 | 0.080 |
Why?
|
| Diabetes Insipidus | 2 | 1987 | 2 | 0.080 |
Why?
|
| Barrett Esophagus | 1 | 2009 | 30 | 0.080 |
Why?
|
| CD55 Antigens | 1 | 2008 | 1 | 0.080 |
Why?
|
| CD59 Antigens | 1 | 2008 | 2 | 0.080 |
Why?
|
| Adolescent | 7 | 2018 | 6229 | 0.080 |
Why?
|
| Sepsis | 1 | 2013 | 286 | 0.080 |
Why?
|
| Gene Rearrangement | 4 | 2014 | 41 | 0.080 |
Why?
|
| Transforming Growth Factor alpha | 2 | 1999 | 15 | 0.080 |
Why?
|
| X Chromosome | 1 | 1989 | 46 | 0.080 |
Why?
|
| Antigen-Antibody Complex | 2 | 1980 | 52 | 0.080 |
Why?
|
| Erythroblasts | 1 | 2008 | 15 | 0.080 |
Why?
|
| Lymphatic Diseases | 2 | 1985 | 13 | 0.070 |
Why?
|
| Glucose | 1 | 2012 | 467 | 0.070 |
Why?
|
| Tissue Embedding | 1 | 2008 | 3 | 0.070 |
Why?
|
| Monocytes | 2 | 2008 | 353 | 0.070 |
Why?
|
| Gene Expression Profiling | 2 | 2016 | 765 | 0.070 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2008 | 19 | 0.070 |
Why?
|
| Virus Diseases | 1 | 2009 | 119 | 0.070 |
Why?
|
| Sp1 Transcription Factor | 1 | 2008 | 21 | 0.070 |
Why?
|
| Apoptosis | 5 | 2016 | 1073 | 0.070 |
Why?
|
| Erythroid Precursor Cells | 1 | 2008 | 23 | 0.070 |
Why?
|
| Lipidoses | 1 | 1988 | 1 | 0.070 |
Why?
|
| Langerhans Cells | 1 | 1988 | 11 | 0.070 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2008 | 18 | 0.070 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 1988 | 16 | 0.070 |
Why?
|
| Viral Matrix Proteins | 3 | 1997 | 50 | 0.070 |
Why?
|
| Polyploidy | 1 | 2008 | 11 | 0.070 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2008 | 63 | 0.070 |
Why?
|
| Mosaicism | 1 | 2008 | 30 | 0.070 |
Why?
|
| Antigens | 4 | 2002 | 147 | 0.070 |
Why?
|
| Actinin | 1 | 1988 | 10 | 0.070 |
Why?
|
| Mice, SCID | 6 | 2008 | 520 | 0.070 |
Why?
|
| Esophageal Neoplasms | 1 | 2009 | 83 | 0.070 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 1988 | 34 | 0.070 |
Why?
|
| Concanavalin A | 3 | 1986 | 40 | 0.070 |
Why?
|
| Immunoproliferative Disorders | 1 | 1987 | 1 | 0.070 |
Why?
|
| Disease Models, Animal | 4 | 2007 | 2179 | 0.070 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2008 | 58 | 0.070 |
Why?
|
| Neutropenia | 1 | 2008 | 67 | 0.070 |
Why?
|
| Follow-Up Studies | 5 | 2016 | 2451 | 0.070 |
Why?
|
| Gene Rearrangement, T-Lymphocyte | 1 | 2007 | 9 | 0.070 |
Why?
|
| Parvovirus B19, Human | 1 | 2007 | 5 | 0.070 |
Why?
|
| mRNA Cleavage and Polyadenylation Factors | 1 | 2008 | 61 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 2007 | 17 | 0.070 |
Why?
|
| Retroperitoneal Fibrosis | 1 | 1987 | 2 | 0.070 |
Why?
|
| Severe Combined Immunodeficiency | 2 | 2000 | 54 | 0.070 |
Why?
|
| Tuberculosis | 1 | 2011 | 295 | 0.070 |
Why?
|
| Th1 Cells | 1 | 2008 | 174 | 0.070 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 1986 | 211 | 0.070 |
Why?
|
| Cytokines | 1 | 1991 | 934 | 0.070 |
Why?
|
| Bone and Bones | 1 | 1988 | 139 | 0.070 |
Why?
|
| Connective Tissue Diseases | 1 | 1987 | 11 | 0.070 |
Why?
|
| Lymph Nodes | 6 | 1999 | 224 | 0.070 |
Why?
|
| Mediastinum | 1 | 1987 | 29 | 0.070 |
Why?
|
| Massachusetts | 5 | 2016 | 2073 | 0.070 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2005 | 296 | 0.070 |
Why?
|
| Phagocytosis | 2 | 1987 | 264 | 0.070 |
Why?
|
| Aging | 4 | 1981 | 746 | 0.070 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2006 | 52 | 0.070 |
Why?
|
| Thrombocytosis | 1 | 2006 | 3 | 0.070 |
Why?
|
| Anemia, Refractory | 1 | 2006 | 2 | 0.060 |
Why?
|
| Neural Tube Defects | 1 | 2006 | 27 | 0.060 |
Why?
|
| Receptors, Fc | 3 | 1983 | 24 | 0.060 |
Why?
|
| Cell Separation | 2 | 1984 | 146 | 0.060 |
Why?
|
| Breast | 1 | 2008 | 183 | 0.060 |
Why?
|
| ErbB Receptors | 2 | 2014 | 114 | 0.060 |
Why?
|
| Neoplasms, Multiple Primary | 2 | 1993 | 31 | 0.060 |
Why?
|
| Repressor Proteins | 2 | 2024 | 347 | 0.060 |
Why?
|
| Translocation, Genetic | 3 | 2016 | 71 | 0.060 |
Why?
|
| Liver | 4 | 2006 | 849 | 0.060 |
Why?
|
| Lymphocyte Activation | 7 | 2008 | 760 | 0.060 |
Why?
|
| Blood Transfusion | 3 | 2001 | 161 | 0.060 |
Why?
|
| Reproducibility of Results | 4 | 2016 | 1645 | 0.060 |
Why?
|
| Jejunal Neoplasms | 1 | 1985 | 3 | 0.060 |
Why?
|
| G(M2) Ganglioside | 1 | 2005 | 10 | 0.060 |
Why?
|
| Mice, Inbred NOD | 5 | 2008 | 525 | 0.060 |
Why?
|
| DNA, Viral | 2 | 2005 | 232 | 0.060 |
Why?
|
| Carcinoma, Small Cell | 1 | 2005 | 22 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 3 | 2011 | 274 | 0.060 |
Why?
|
| Transplantation, Heterologous | 2 | 2008 | 229 | 0.060 |
Why?
|
| Lymphoma, T-Cell | 2 | 1998 | 24 | 0.060 |
Why?
|
| Primary Myelofibrosis | 1 | 1985 | 11 | 0.060 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2012 | 349 | 0.060 |
Why?
|
| Dendrites | 1 | 1985 | 56 | 0.060 |
Why?
|
| Immunization, Passive | 1 | 2005 | 105 | 0.060 |
Why?
|
| Antineoplastic Agents | 2 | 2006 | 660 | 0.060 |
Why?
|
| Treatment Outcome | 5 | 2018 | 5625 | 0.060 |
Why?
|
| Papillomaviridae | 1 | 2005 | 59 | 0.060 |
Why?
|
| Rats, Inbred BN | 3 | 1981 | 26 | 0.060 |
Why?
|
| Receptors, Antigen | 2 | 1984 | 7 | 0.060 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2024 | 28 | 0.050 |
Why?
|
| Thymoma | 1 | 1984 | 12 | 0.050 |
Why?
|
| Diabetes Mellitus | 2 | 2007 | 537 | 0.050 |
Why?
|
| Thymus Neoplasms | 1 | 1984 | 22 | 0.050 |
Why?
|
| Endocytosis | 2 | 1982 | 152 | 0.050 |
Why?
|
| Cell Differentiation | 2 | 2008 | 1348 | 0.050 |
Why?
|
| Retrospective Studies | 6 | 2016 | 6595 | 0.050 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2024 | 83 | 0.050 |
Why?
|
| Cytotoxicity, Immunologic | 4 | 1990 | 148 | 0.050 |
Why?
|
| Gene Expression | 3 | 2007 | 837 | 0.050 |
Why?
|
| Nevus, Pigmented | 1 | 2003 | 19 | 0.050 |
Why?
|
| Androgen Antagonists | 1 | 2003 | 22 | 0.050 |
Why?
|
| Receptors, Androgen | 1 | 2003 | 31 | 0.050 |
Why?
|
| Poly I-C | 4 | 2009 | 76 | 0.050 |
Why?
|
| Cell Proliferation | 3 | 2011 | 980 | 0.050 |
Why?
|
| RNA, Messenger | 5 | 2005 | 1536 | 0.050 |
Why?
|
| Inflammation | 4 | 1994 | 1144 | 0.050 |
Why?
|
| Trifluoperazine | 1 | 1982 | 3 | 0.050 |
Why?
|
| Prostatic Hyperplasia | 1 | 2002 | 20 | 0.050 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2003 | 131 | 0.050 |
Why?
|
| Infant | 4 | 2016 | 1649 | 0.050 |
Why?
|
| Lymphocytic choriomeningitis virus | 2 | 2000 | 89 | 0.050 |
Why?
|
| Transplantation Tolerance | 1 | 2002 | 65 | 0.050 |
Why?
|
| Bone Marrow Examination | 3 | 2014 | 8 | 0.050 |
Why?
|
| Phosphorylation | 2 | 2016 | 937 | 0.050 |
Why?
|
| Germinoma | 1 | 2001 | 1 | 0.050 |
Why?
|
| DNA Methylation | 2 | 2014 | 292 | 0.050 |
Why?
|
| Splenic Neoplasms | 1 | 1981 | 8 | 0.050 |
Why?
|
| Eye Neoplasms | 1 | 2001 | 17 | 0.050 |
Why?
|
| Retinoblastoma | 1 | 2001 | 28 | 0.050 |
Why?
|
| Leiomyosarcoma | 1 | 2001 | 9 | 0.050 |
Why?
|
| Fibroblasts | 3 | 2016 | 387 | 0.050 |
Why?
|
| Testicular Neoplasms | 1 | 2001 | 33 | 0.050 |
Why?
|
| CD8 Antigens | 3 | 2002 | 54 | 0.040 |
Why?
|
| Mice, Transgenic | 3 | 2016 | 1275 | 0.040 |
Why?
|
| Neoplasms, Second Primary | 1 | 2001 | 47 | 0.040 |
Why?
|
| Vincristine | 2 | 2014 | 27 | 0.040 |
Why?
|
| HLA Antigens | 1 | 1981 | 63 | 0.040 |
Why?
|
| Cyclophosphamide | 2 | 2014 | 79 | 0.040 |
Why?
|
| ras Proteins | 2 | 2014 | 77 | 0.040 |
Why?
|
| Prednisone | 2 | 2014 | 86 | 0.040 |
Why?
|
| Fluorescent Antibody Technique | 6 | 1998 | 233 | 0.040 |
Why?
|
| DNA, Neoplasm | 3 | 2003 | 57 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 6 | 2002 | 881 | 0.040 |
Why?
|
| Doxorubicin | 2 | 2014 | 99 | 0.040 |
Why?
|
| NF-kappa B | 2 | 2008 | 469 | 0.040 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 2 | 2012 | 26 | 0.040 |
Why?
|
| Transplantation Chimera | 1 | 2000 | 40 | 0.040 |
Why?
|
| Molecular Weight | 3 | 2002 | 187 | 0.040 |
Why?
|
| Syndrome | 3 | 1990 | 180 | 0.040 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2001 | 641 | 0.040 |
Why?
|
| Transcription Factors | 1 | 2008 | 1513 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2016 | 2560 | 0.040 |
Why?
|
| Cell Count | 2 | 2011 | 130 | 0.040 |
Why?
|
| Blood Platelets | 1 | 2001 | 102 | 0.040 |
Why?
|
| Microspheres | 3 | 2005 | 56 | 0.040 |
Why?
|
| Antigens, CD | 3 | 2007 | 347 | 0.040 |
Why?
|
| Transplantation, Homologous | 1 | 2000 | 243 | 0.040 |
Why?
|
| Biomarkers | 3 | 2010 | 1393 | 0.040 |
Why?
|
| Anesthetics, Local | 1 | 1980 | 71 | 0.040 |
Why?
|
| Age Factors | 2 | 2018 | 1559 | 0.040 |
Why?
|
| Fluorescent Antibody Technique, Direct | 2 | 2009 | 9 | 0.040 |
Why?
|
| Infectious Mononucleosis | 3 | 1989 | 34 | 0.040 |
Why?
|
| Breast Neoplasms | 1 | 2008 | 1199 | 0.040 |
Why?
|
| Cervix Uteri | 2 | 2011 | 60 | 0.040 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 1999 | 33 | 0.040 |
Why?
|
| Colchicine | 5 | 1987 | 28 | 0.040 |
Why?
|
| Child | 6 | 2006 | 4520 | 0.040 |
Why?
|
| Rituximab | 2 | 2012 | 87 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 1996 | 103 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2001 | 1606 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2005 | 542 | 0.040 |
Why?
|
| Keratins | 3 | 2004 | 31 | 0.040 |
Why?
|
| Transplantation Conditioning | 3 | 2008 | 102 | 0.040 |
Why?
|
| Reference Values | 1 | 1999 | 335 | 0.040 |
Why?
|
| Mice, Knockout | 3 | 2012 | 2107 | 0.040 |
Why?
|
| Remission Induction | 1 | 2018 | 147 | 0.040 |
Why?
|
| Stem Cell Transplantation | 1 | 2018 | 79 | 0.040 |
Why?
|
| Hypohidrosis | 1 | 1998 | 4 | 0.040 |
Why?
|
| Immunity, Innate | 5 | 2000 | 796 | 0.040 |
Why?
|
| Cytomegalovirus Infections | 3 | 2009 | 66 | 0.040 |
Why?
|
| Centrosome | 1 | 1998 | 70 | 0.040 |
Why?
|
| Alopecia | 1 | 1998 | 25 | 0.040 |
Why?
|
| Cell Transformation, Viral | 2 | 1996 | 15 | 0.040 |
Why?
|
| Sweat Gland Neoplasms | 1 | 1998 | 20 | 0.040 |
Why?
|
| Ileal Neoplasms | 1 | 1997 | 3 | 0.040 |
Why?
|
| Pruritus | 1 | 1998 | 30 | 0.040 |
Why?
|
| Sjogren's Syndrome | 1 | 1998 | 24 | 0.040 |
Why?
|
| Melanocytes | 2 | 2012 | 76 | 0.040 |
Why?
|
| Cells, Cultured | 5 | 1995 | 2152 | 0.040 |
Why?
|
| Carcinoid Tumor | 1 | 1997 | 13 | 0.030 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2018 | 72 | 0.030 |
Why?
|
| Cricetinae | 2 | 2011 | 366 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 3 | 1998 | 453 | 0.030 |
Why?
|
| Immunologic Techniques | 1 | 1977 | 11 | 0.030 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 2 | 2008 | 35 | 0.030 |
Why?
|
| Radiography, Abdominal | 1 | 1997 | 26 | 0.030 |
Why?
|
| Cell Line | 10 | 1993 | 2036 | 0.030 |
Why?
|
| Child, Preschool | 3 | 2010 | 1988 | 0.030 |
Why?
|
| Leukocyte Count | 2 | 1995 | 97 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2008 | 613 | 0.030 |
Why?
|
| Neovascularization, Pathologic | 1 | 1997 | 139 | 0.030 |
Why?
|
| History, 17th Century | 1 | 2016 | 6 | 0.030 |
Why?
|
| Combined Modality Therapy | 2 | 2012 | 371 | 0.030 |
Why?
|
| Janus Kinase 2 | 2 | 2006 | 16 | 0.030 |
Why?
|
| Tetrasomy | 1 | 2016 | 3 | 0.030 |
Why?
|
| Immunoblastic Lymphadenopathy | 1 | 1996 | 1 | 0.030 |
Why?
|
| Proteins | 1 | 2002 | 751 | 0.030 |
Why?
|
| Tuberculosis, Miliary | 1 | 1996 | 3 | 0.030 |
Why?
|
| Antigens, Viral | 2 | 1987 | 135 | 0.030 |
Why?
|
| Multivariate Analysis | 2 | 2011 | 934 | 0.030 |
Why?
|
| Lymphoma, AIDS-Related | 1 | 1996 | 8 | 0.030 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2016 | 51 | 0.030 |
Why?
|
| Lipopolysaccharides | 2 | 2012 | 625 | 0.030 |
Why?
|
| HeLa Cells | 3 | 2011 | 535 | 0.030 |
Why?
|
| Exons | 1 | 2016 | 199 | 0.030 |
Why?
|
| Bronchi | 1 | 1996 | 77 | 0.030 |
Why?
|
| Intestine, Large | 1 | 1995 | 7 | 0.030 |
Why?
|
| Observer Variation | 1 | 2016 | 213 | 0.030 |
Why?
|
| Tumor Microenvironment | 1 | 2016 | 158 | 0.030 |
Why?
|
| In Vitro Techniques | 4 | 1990 | 487 | 0.030 |
Why?
|
| DNA | 2 | 2006 | 830 | 0.030 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2016 | 262 | 0.030 |
Why?
|
| Cell Fusion | 1 | 1995 | 37 | 0.030 |
Why?
|
| CD5 Antigens | 2 | 1993 | 18 | 0.030 |
Why?
|
| Lymphoid Tissue | 3 | 2002 | 55 | 0.030 |
Why?
|
| Kidney Transplantation | 1 | 1997 | 317 | 0.030 |
Why?
|
| Prospective Studies | 3 | 2009 | 3270 | 0.030 |
Why?
|
| Tissue Fixation | 1 | 2014 | 20 | 0.030 |
Why?
|
| Alcohols | 1 | 2014 | 13 | 0.030 |
Why?
|
| Colitis, Ulcerative | 1 | 1995 | 74 | 0.030 |
Why?
|
| Formaldehyde | 1 | 2014 | 31 | 0.030 |
Why?
|
| Leukemia, Megakaryoblastic, Acute | 1 | 1994 | 1 | 0.030 |
Why?
|
| Syndecan-1 | 1 | 2014 | 9 | 0.030 |
Why?
|
| Lipids | 2 | 2012 | 316 | 0.030 |
Why?
|
| Acute Disease | 4 | 1995 | 671 | 0.030 |
Why?
|
| Cytodiagnosis | 1 | 2014 | 46 | 0.030 |
Why?
|
| Antibodies, Anti-Idiotypic | 2 | 1984 | 33 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 21 | 1 | 1994 | 29 | 0.030 |
Why?
|
| Papanicolaou Test | 1 | 2014 | 42 | 0.030 |
Why?
|
| Signal Transduction | 2 | 2016 | 3033 | 0.030 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 2 | 1991 | 109 | 0.030 |
Why?
|
| Thy-1 Antigens | 2 | 1984 | 21 | 0.030 |
Why?
|
| Polyomavirus | 1 | 1994 | 24 | 0.030 |
Why?
|
| Crohn Disease | 1 | 1995 | 111 | 0.030 |
Why?
|
| Bile Duct Neoplasms | 1 | 2014 | 46 | 0.030 |
Why?
|
| Solubility | 2 | 1984 | 179 | 0.030 |
Why?
|
| Aneuploidy | 1 | 1994 | 42 | 0.030 |
Why?
|
| Polyomavirus Infections | 1 | 1994 | 45 | 0.030 |
Why?
|
| In Situ Hybridization | 1 | 1994 | 216 | 0.030 |
Why?
|
| Ovarian Neoplasms | 1 | 1995 | 145 | 0.030 |
Why?
|
| Automation | 2 | 2003 | 54 | 0.030 |
Why?
|
| Macrophage Activation Syndrome | 1 | 2013 | 5 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2014 | 207 | 0.030 |
Why?
|
| Clinical Laboratory Techniques | 2 | 2003 | 45 | 0.030 |
Why?
|
| Biotechnology | 2 | 2003 | 43 | 0.030 |
Why?
|
| Bromodeoxyuridine | 1 | 1993 | 42 | 0.030 |
Why?
|
| Deoxyribonuclease I | 1 | 1993 | 41 | 0.030 |
Why?
|
| Tandem Repeat Sequences | 1 | 2012 | 26 | 0.030 |
Why?
|
| CpG Islands | 1 | 2014 | 216 | 0.020 |
Why?
|
| Gene Duplication | 1 | 2012 | 34 | 0.020 |
Why?
|
| Cytarabine | 1 | 2012 | 35 | 0.020 |
Why?
|
| Collagen | 2 | 2005 | 123 | 0.020 |
Why?
|
| Eosinophils | 1 | 1993 | 46 | 0.020 |
Why?
|
| Cytochalasins | 3 | 1981 | 4 | 0.020 |
Why?
|
| Arthritis, Rheumatoid | 1 | 1976 | 334 | 0.020 |
Why?
|
| Cell Division | 3 | 2003 | 449 | 0.020 |
Why?
|
| Plasma Cells | 1 | 1993 | 53 | 0.020 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 1993 | 73 | 0.020 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2012 | 25 | 0.020 |
Why?
|
| Mice, 129 Strain | 1 | 2012 | 41 | 0.020 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2012 | 42 | 0.020 |
Why?
|
| Receptors, Concanavalin A | 2 | 1982 | 2 | 0.020 |
Why?
|
| Cerebellar Neoplasms | 1 | 1992 | 10 | 0.020 |
Why?
|
| Protein Stability | 1 | 2012 | 91 | 0.020 |
Why?
|
| Serine | 1 | 2012 | 91 | 0.020 |
Why?
|
| Point Mutation | 3 | 1997 | 166 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 2 | 2003 | 310 | 0.020 |
Why?
|
| Fasting | 1 | 2012 | 51 | 0.020 |
Why?
|
| Histocompatibility Antigens Class II | 2 | 1984 | 182 | 0.020 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2011 | 25 | 0.020 |
Why?
|
| Macrophages, Peritoneal | 1 | 2012 | 77 | 0.020 |
Why?
|
| Intestine, Small | 1 | 2012 | 79 | 0.020 |
Why?
|
| Glucose Tolerance Test | 1 | 2012 | 97 | 0.020 |
Why?
|
| Membrane Fluidity | 2 | 1982 | 15 | 0.020 |
Why?
|
| Pleura | 1 | 2011 | 12 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2012 | 380 | 0.020 |
Why?
|
| Autoantibodies | 3 | 1987 | 182 | 0.020 |
Why?
|
| Mice, Inbred CBA | 2 | 2002 | 83 | 0.020 |
Why?
|
| Peritoneum | 1 | 2011 | 29 | 0.020 |
Why?
|
| Thymus Gland | 1 | 2012 | 233 | 0.020 |
Why?
|
| Endometrium | 1 | 2011 | 30 | 0.020 |
Why?
|
| Adiposity | 1 | 2012 | 83 | 0.020 |
Why?
|
| Chronic Disease | 2 | 2008 | 752 | 0.020 |
Why?
|
| Virus Physiological Phenomena | 1 | 1991 | 8 | 0.020 |
Why?
|
| Frozen Sections | 2 | 2003 | 10 | 0.020 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1991 | 98 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2012 | 186 | 0.020 |
Why?
|
| Hypoglycemia | 1 | 2012 | 65 | 0.020 |
Why?
|
| Blotting, Northern | 1 | 1991 | 150 | 0.020 |
Why?
|
| Hyperplasia | 1 | 2011 | 88 | 0.020 |
Why?
|
| NADPH Oxidase 2 | 1 | 2011 | 35 | 0.020 |
Why?
|
| California | 1 | 2011 | 174 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2014 | 674 | 0.020 |
Why?
|
| Qa-SNARE Proteins | 1 | 2010 | 19 | 0.020 |
Why?
|
| Antigens, Differentiation | 1 | 1991 | 138 | 0.020 |
Why?
|
| Dietary Fats | 1 | 2012 | 175 | 0.020 |
Why?
|
| Perforin | 1 | 2010 | 31 | 0.020 |
Why?
|
| Gastritis | 1 | 2010 | 18 | 0.020 |
Why?
|
| Contractile Proteins | 2 | 1980 | 14 | 0.020 |
Why?
|
| Cricetulus | 1 | 2011 | 99 | 0.020 |
Why?
|
| Goats | 2 | 1981 | 11 | 0.020 |
Why?
|
| CHO Cells | 1 | 2011 | 188 | 0.020 |
Why?
|
| Fatty Acids | 1 | 2012 | 200 | 0.020 |
Why?
|
| Interleukin-1 | 1 | 1991 | 156 | 0.020 |
Why?
|
| Tryptophan | 1 | 1990 | 57 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2012 | 359 | 0.020 |
Why?
|
| Hemocyanins | 2 | 1980 | 23 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 1997 | 1293 | 0.020 |
Why?
|
| Muscular Diseases | 1 | 1990 | 50 | 0.020 |
Why?
|
| Body Weight | 1 | 2012 | 377 | 0.020 |
Why?
|
| Parvoviridae Infections | 1 | 1990 | 23 | 0.020 |
Why?
|
| Ligands | 2 | 2000 | 416 | 0.020 |
Why?
|
| Base Sequence | 3 | 2003 | 1329 | 0.020 |
Why?
|
| Enterovirus B, Human | 1 | 2009 | 17 | 0.020 |
Why?
|
| Enterovirus Infections | 1 | 2009 | 12 | 0.020 |
Why?
|
| Disease Susceptibility | 2 | 1987 | 165 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 1991 | 320 | 0.020 |
Why?
|
| Cell Movement | 1 | 2011 | 450 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2009 | 8 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2009 | 10 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2009 | 19 | 0.020 |
Why?
|
| Pancreas | 1 | 2010 | 150 | 0.020 |
Why?
|
| Vaccinia virus | 1 | 2009 | 71 | 0.020 |
Why?
|
| Mucous Membrane | 1 | 2009 | 22 | 0.020 |
Why?
|
| Cisplatin | 1 | 1990 | 139 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2011 | 337 | 0.020 |
Why?
|
| Esophagus | 1 | 2009 | 50 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2011 | 730 | 0.020 |
Why?
|
| Protein Biosynthesis | 2 | 2002 | 317 | 0.020 |
Why?
|
| Genetic Linkage | 1 | 1989 | 96 | 0.020 |
Why?
|
| Risk Factors | 2 | 2012 | 5331 | 0.020 |
Why?
|
| Mitosis | 2 | 2008 | 214 | 0.020 |
Why?
|
| United States | 2 | 2014 | 7824 | 0.020 |
Why?
|
| Models, Animal | 1 | 2009 | 236 | 0.020 |
Why?
|
| Antibodies, Viral | 2 | 1990 | 325 | 0.020 |
Why?
|
| Lymphopoiesis | 1 | 2008 | 27 | 0.020 |
Why?
|
| Histological Techniques | 1 | 2008 | 18 | 0.020 |
Why?
|
| Cell Cycle | 2 | 1990 | 389 | 0.020 |
Why?
|
| Ultrasonography | 1 | 1991 | 481 | 0.020 |
Why?
|
| Sclerosis | 1 | 1988 | 9 | 0.020 |
Why?
|
| Leukopenia | 1 | 2008 | 16 | 0.020 |
Why?
|
| Actins | 2 | 2001 | 259 | 0.020 |
Why?
|
| Isoelectric Point | 1 | 1988 | 12 | 0.020 |
Why?
|
| Chemical Precipitation | 1 | 1988 | 12 | 0.020 |
Why?
|
| Genes, Dominant | 1 | 2008 | 57 | 0.020 |
Why?
|
| Paraproteinemias | 1 | 2008 | 16 | 0.020 |
Why?
|
| RNA Interference | 1 | 2011 | 618 | 0.020 |
Why?
|
| Risk | 1 | 2008 | 377 | 0.020 |
Why?
|
| Granulocytes | 1 | 2008 | 71 | 0.020 |
Why?
|
| Histocytochemistry | 2 | 1986 | 47 | 0.020 |
Why?
|
| Insulin | 1 | 2012 | 686 | 0.020 |
Why?
|
| Histiocytes | 1 | 1987 | 5 | 0.020 |
Why?
|
| NIH 3T3 Cells | 1 | 2008 | 99 | 0.020 |
Why?
|
| Epitopes | 2 | 2005 | 289 | 0.020 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 1987 | 30 | 0.020 |
Why?
|
| Radiation Dosage | 1 | 1988 | 132 | 0.020 |
Why?
|
| Pedigree | 1 | 2008 | 193 | 0.020 |
Why?
|
| Mutagenesis | 1 | 2008 | 132 | 0.020 |
Why?
|
| Pancytopenia | 1 | 1987 | 7 | 0.020 |
Why?
|
| Intermediate Filament Proteins | 1 | 1987 | 19 | 0.020 |
Why?
|
| Cell Culture Techniques | 1 | 2008 | 182 | 0.020 |
Why?
|
| Intermediate Filaments | 1 | 1986 | 10 | 0.020 |
Why?
|
| Age Distribution | 1 | 2007 | 259 | 0.020 |
Why?
|
| Leukemia, Radiation-Induced | 1 | 1986 | 1 | 0.020 |
Why?
|
| Molecular Sequence Data | 2 | 2003 | 1989 | 0.020 |
Why?
|
| Sequence Deletion | 2 | 1997 | 117 | 0.020 |
Why?
|
| Cell Survival | 3 | 1990 | 568 | 0.020 |
Why?
|
| Cytogenetic Analysis | 1 | 2006 | 25 | 0.020 |
Why?
|
| Fibrosis | 1 | 1987 | 160 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2008 | 700 | 0.020 |
Why?
|
| Risk Assessment | 2 | 2003 | 2066 | 0.020 |
Why?
|
| Radiography | 1 | 1988 | 540 | 0.020 |
Why?
|
| Leukemia, Lymphoid | 1 | 1985 | 11 | 0.020 |
Why?
|
| Orchiectomy | 1 | 2005 | 33 | 0.020 |
Why?
|
| Interleukin-2 | 1 | 1986 | 166 | 0.020 |
Why?
|
| Mice, Inbred AKR | 1 | 2005 | 12 | 0.020 |
Why?
|
| Immunity, Cellular | 1 | 1986 | 175 | 0.020 |
Why?
|
| S100 Proteins | 1 | 1985 | 19 | 0.010 |
Why?
|
| Avian Leukosis Virus | 1 | 1985 | 3 | 0.010 |
Why?
|
| Kinetics | 2 | 2002 | 760 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2009 | 625 | 0.010 |
Why?
|
| Jurkat Cells | 1 | 2005 | 110 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 2005 | 102 | 0.010 |
Why?
|
| Arthritis | 1 | 2005 | 53 | 0.010 |
Why?
|
| Pituitary Gland, Posterior | 1 | 1985 | 17 | 0.010 |
Why?
|
| Hemangiosarcoma | 1 | 1985 | 25 | 0.010 |
Why?
|
| Pituitary Gland | 2 | 1987 | 51 | 0.010 |
Why?
|
| Skin | 3 | 1990 | 373 | 0.010 |
Why?
|
| Hematopoietic Stem Cells | 1 | 1986 | 285 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2008 | 658 | 0.010 |
Why?
|
| Bone Neoplasms | 1 | 2005 | 125 | 0.010 |
Why?
|
| Liposomes | 1 | 1984 | 107 | 0.010 |
Why?
|
| Radiographic Image Enhancement | 1 | 1984 | 98 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2008 | 1355 | 0.010 |
Why?
|
| Dose-Response Relationship, Radiation | 3 | 1990 | 52 | 0.010 |
Why?
|
| Octoxynol | 1 | 1983 | 11 | 0.010 |
Why?
|
| Cytomegalovirus | 1 | 1984 | 91 | 0.010 |
Why?
|
| Hepatitis, Viral, Animal | 1 | 1983 | 1 | 0.010 |
Why?
|
| HIV Infections | 1 | 2011 | 967 | 0.010 |
Why?
|
| DNA Probes | 1 | 2003 | 34 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 2003 | 34 | 0.010 |
Why?
|
| Incidence | 1 | 2007 | 1372 | 0.010 |
Why?
|
| Transduction, Genetic | 1 | 1985 | 237 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2008 | 1543 | 0.010 |
Why?
|
| Probability | 1 | 2003 | 170 | 0.010 |
Why?
|
| Diffusion | 1 | 1983 | 82 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2003 | 240 | 0.010 |
Why?
|
| Prostatectomy | 1 | 2003 | 88 | 0.010 |
Why?
|
| Genotype | 1 | 2005 | 664 | 0.010 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily B | 1 | 2002 | 8 | 0.010 |
Why?
|
| Injections, Intraperitoneal | 1 | 2002 | 47 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 1992 | 2162 | 0.010 |
Why?
|
| Radiation Chimera | 1 | 2002 | 58 | 0.010 |
Why?
|
| Antibodies, Blocking | 1 | 2002 | 39 | 0.010 |
Why?
|
| Antigens, Ly | 1 | 2002 | 42 | 0.010 |
Why?
|
| Polyethylene Glycols | 1 | 1983 | 168 | 0.010 |
Why?
|
| Pregnancy | 1 | 2009 | 2328 | 0.010 |
Why?
|
| Equipment Design | 1 | 2003 | 345 | 0.010 |
Why?
|
| Contrast Media | 1 | 1984 | 423 | 0.010 |
Why?
|
| Desmin | 1 | 2001 | 5 | 0.010 |
Why?
|
| Cyclin D1 | 1 | 2001 | 17 | 0.010 |
Why?
|
| Lectins, C-Type | 1 | 2002 | 89 | 0.010 |
Why?
|
| Retinoblastoma Protein | 1 | 2001 | 37 | 0.010 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2002 | 119 | 0.010 |
Why?
|
| Hematuria | 1 | 2001 | 22 | 0.010 |
Why?
|
| Ovariectomy | 1 | 2001 | 102 | 0.010 |
Why?
|
| Viral Load | 1 | 2002 | 231 | 0.010 |
Why?
|
| Cystectomy | 1 | 2001 | 31 | 0.010 |
Why?
|
| Immunoglobulin gamma-Chains | 1 | 1981 | 5 | 0.010 |
Why?
|
| Immunoglobulin mu-Chains | 1 | 1981 | 13 | 0.010 |
Why?
|
| Sulfur Radioisotopes | 1 | 2001 | 12 | 0.010 |
Why?
|
| beta 2-Microglobulin | 1 | 1981 | 49 | 0.010 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 2001 | 23 | 0.010 |
Why?
|
| Platelet Aggregation | 1 | 2001 | 24 | 0.010 |
Why?
|
| Hysterectomy | 1 | 2001 | 67 | 0.010 |
Why?
|
| Cell Lineage | 1 | 2002 | 268 | 0.010 |
Why?
|
| Adenosine Diphosphate | 1 | 2001 | 42 | 0.010 |
Why?
|
| Sarcoma, Experimental | 1 | 1980 | 6 | 0.010 |
Why?
|
| Binding Sites, Antibody | 1 | 1980 | 22 | 0.010 |
Why?
|
| Fluoresceins | 1 | 1980 | 30 | 0.010 |
Why?
|
| Peritoneal Cavity | 1 | 2000 | 31 | 0.010 |
Why?
|
| Serum Albumin, Bovine | 1 | 1980 | 35 | 0.010 |
Why?
|
| Clonal Anergy | 1 | 2000 | 23 | 0.010 |
Why?
|
| Chlorpromazine | 1 | 1980 | 8 | 0.010 |
Why?
|
| CD40 Antigens | 1 | 2000 | 60 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 2000 | 99 | 0.010 |
Why?
|
| Adrenal Cortex | 1 | 1980 | 3 | 0.010 |
Why?
|
| Interferon Inducers | 1 | 2000 | 11 | 0.010 |
Why?
|
| Survivors | 1 | 2001 | 170 | 0.010 |
Why?
|
| Leukocyte Transfusion | 1 | 2000 | 16 | 0.010 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2000 | 42 | 0.010 |
Why?
|
| Pichinde virus | 1 | 2000 | 20 | 0.010 |
Why?
|
| Lidocaine | 1 | 1980 | 33 | 0.010 |
Why?
|
| Antibodies | 1 | 2001 | 182 | 0.010 |
Why?
|
| Interphase | 1 | 2000 | 66 | 0.010 |
Why?
|
| Adoptive Transfer | 1 | 2000 | 148 | 0.010 |
Why?
|
| Amino Acids | 1 | 2001 | 146 | 0.010 |
Why?
|
| Cattle | 1 | 1980 | 307 | 0.010 |
Why?
|
| Antigen-Presenting Cells | 1 | 2000 | 178 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2003 | 1121 | 0.010 |
Why?
|
| Thymectomy | 1 | 1999 | 34 | 0.010 |
Why?
|
| Hyperglycemia | 1 | 2000 | 104 | 0.010 |
Why?
|
| Rabbits | 1 | 1979 | 332 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 1999 | 197 | 0.010 |
Why?
|
| Carbenicillin | 1 | 1978 | 3 | 0.010 |
Why?
|
| Staining and Labeling | 1 | 1999 | 125 | 0.010 |
Why?
|
| Nephritis, Interstitial | 1 | 1978 | 15 | 0.010 |
Why?
|
| Tissue Donors | 1 | 1999 | 152 | 0.010 |
Why?
|
| Recurrence | 1 | 2000 | 639 | 0.010 |
Why?
|
| Myocardium | 1 | 1980 | 274 | 0.010 |
Why?
|
| Immunotoxins | 1 | 1997 | 7 | 0.010 |
Why?
|
| Factor VIII | 1 | 1997 | 32 | 0.010 |
Why?
|
| Glomerulonephritis, IGA | 1 | 1997 | 8 | 0.010 |
Why?
|
| Virus Latency | 1 | 1997 | 32 | 0.010 |
Why?
|
| Haplorhini | 1 | 1977 | 14 | 0.010 |
Why?
|
| Interferons | 2 | 1991 | 73 | 0.010 |
Why?
|
| Living Donors | 1 | 1997 | 77 | 0.010 |
Why?
|
| Lung Diseases | 1 | 1998 | 182 | 0.010 |
Why?
|
| Cytochalasin D | 3 | 1981 | 18 | 0.010 |
Why?
|
| Sheep | 1 | 1977 | 179 | 0.010 |
Why?
|
| Amino Acid Substitution | 1 | 1997 | 240 | 0.010 |
Why?
|
| Cross Reactions | 2 | 1987 | 130 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 1979 | 459 | 0.010 |
Why?
|
| Synovial Fluid | 1 | 1976 | 29 | 0.010 |
Why?
|
| Rosette Formation | 2 | 1986 | 12 | 0.010 |
Why?
|
| HIV Seronegativity | 1 | 1996 | 19 | 0.010 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 1996 | 48 | 0.010 |
Why?
|
| Half-Life | 1 | 1996 | 80 | 0.010 |
Why?
|
| Complement System Proteins | 1 | 1976 | 105 | 0.010 |
Why?
|
| Glomerulonephritis | 1 | 1976 | 32 | 0.010 |
Why?
|
| Models, Biological | 1 | 2001 | 1176 | 0.010 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2000 | 674 | 0.010 |
Why?
|
| Selection, Genetic | 1 | 1996 | 83 | 0.010 |
Why?
|
| Genetic Variation | 1 | 1997 | 383 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 1996 | 299 | 0.010 |
Why?
|
| Antigens, Bacterial | 1 | 1976 | 199 | 0.010 |
Why?
|
| Regeneration | 1 | 1995 | 94 | 0.010 |
Why?
|
| Staphylococcus aureus | 1 | 1976 | 176 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 1996 | 670 | 0.010 |
Why?
|
| Down-Regulation | 1 | 1995 | 319 | 0.010 |
Why?
|
| Cell Death | 1 | 1995 | 284 | 0.010 |
Why?
|
| Cholesterol | 1 | 1995 | 260 | 0.010 |
Why?
|
| Blotting, Southern | 1 | 1993 | 55 | 0.010 |
Why?
|
| Formamides | 1 | 1993 | 1 | 0.010 |
Why?
|
| Exonucleases | 1 | 1993 | 5 | 0.010 |
Why?
|
| Single-Strand Specific DNA and RNA Endonucleases | 1 | 1993 | 5 | 0.010 |
Why?
|
| Brain Neoplasms | 1 | 1996 | 308 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 1996 | 1591 | 0.010 |
Why?
|
| Endonucleases | 1 | 1993 | 82 | 0.010 |
Why?
|
| Causality | 1 | 1991 | 58 | 0.010 |
Why?
|
| Self Medication | 1 | 1990 | 14 | 0.010 |
Why?
|
| Rats, Inbred WF | 1 | 1990 | 56 | 0.010 |
Why?
|
| Parvoviridae | 1 | 1990 | 5 | 0.010 |
Why?
|
| Gamma Rays | 1 | 1990 | 32 | 0.010 |
Why?
|
| Colony-Forming Units Assay | 1 | 1990 | 27 | 0.010 |
Why?
|
| Clone Cells | 1 | 1990 | 114 | 0.010 |
Why?
|
| Platinum | 1 | 1990 | 20 | 0.010 |
Why?
|
| Viruses | 1 | 1991 | 80 | 0.010 |
Why?
|
| Glutathione | 1 | 1990 | 54 | 0.010 |
Why?
|
| Sulfhydryl Compounds | 1 | 1990 | 48 | 0.010 |
Why?
|
| Species Specificity | 1 | 1990 | 333 | 0.000 |
Why?
|
| Muscles | 1 | 1990 | 179 | 0.000 |
Why?
|
| Drug Resistance | 1 | 1990 | 149 | 0.000 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1990 | 451 | 0.000 |
Why?
|
| Pituitary Neoplasms | 1 | 1987 | 21 | 0.000 |
Why?
|
| Phosphonoacetic Acid | 1 | 1987 | 1 | 0.000 |
Why?
|
| Cytochalasin B | 1 | 1987 | 23 | 0.000 |
Why?
|
| Vimentin | 1 | 1987 | 18 | 0.000 |
Why?
|
| Colony-Stimulating Factors | 1 | 1986 | 5 | 0.000 |
Why?
|
| Interleukin-3 | 1 | 1986 | 20 | 0.000 |
Why?
|
| Growth Substances | 1 | 1986 | 34 | 0.000 |
Why?
|
| X-Rays | 1 | 1986 | 46 | 0.000 |
Why?
|
| Lymphokines | 1 | 1986 | 66 | 0.000 |
Why?
|
| Avian Leukosis | 1 | 1985 | 1 | 0.000 |
Why?
|
| Chickens | 1 | 1985 | 94 | 0.000 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 1986 | 287 | 0.000 |
Why?
|
| Mitogens | 1 | 1984 | 10 | 0.000 |
Why?
|
| Leukemia, Experimental | 1 | 1984 | 19 | 0.000 |
Why?
|
| Metrizamide | 1 | 1984 | 4 | 0.000 |
Why?
|
| Diatrizoate | 1 | 1984 | 4 | 0.000 |
Why?
|
| Diatrizoate Meglumine | 1 | 1984 | 6 | 0.000 |
Why?
|
| Iothalamate Meglumine | 1 | 1984 | 2 | 0.000 |
Why?
|
| Triiodobenzoic Acids | 1 | 1984 | 11 | 0.000 |
Why?
|
| Thyroiditis | 1 | 1984 | 11 | 0.000 |
Why?
|
| Drug Combinations | 1 | 1984 | 165 | 0.000 |
Why?
|
| Mice, Mutant Strains | 1 | 1984 | 302 | 0.000 |
Why?
|
| Vaccinia | 1 | 1983 | 32 | 0.000 |
Why?
|
| Pancreatitis | 1 | 1984 | 97 | 0.000 |
Why?
|
| Mice, Inbred C3H | 1 | 1983 | 176 | 0.000 |
Why?
|
| Isoantigens | 1 | 1981 | 71 | 0.000 |
Why?
|
| Transplantation, Isogeneic | 1 | 1980 | 8 | 0.000 |
Why?
|
| Neoplasms, Experimental | 1 | 1980 | 77 | 0.000 |
Why?
|
| Microscopy, Electron | 1 | 1980 | 250 | 0.000 |
Why?
|
| Gene Expression Regulation | 1 | 1987 | 1614 | 0.000 |
Why?
|
| Receptors, Immunologic | 1 | 1980 | 177 | 0.000 |
Why?
|
| Microscopy, Fluorescence | 1 | 1981 | 400 | 0.000 |
Why?
|
| Microtubules | 1 | 1980 | 209 | 0.000 |
Why?
|
| Kidney Glomerulus | 1 | 1976 | 22 | 0.000 |
Why?
|
| Kidney | 1 | 1978 | 444 | 0.000 |
Why?
|
| Endocarditis, Bacterial | 1 | 1976 | 36 | 0.000 |
Why?
|